Tivozanib Fails to Show Overall Survival Difference in Metastatic RCC

The results of the study comparing Aveo’s tivozanib to sorafenib for the treatment of metastatic renal cell carcinoma showed no improvement in overall survival, the basis for the FDA’s rejection of the company’s new drug application earlier this year.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news